Just another WordPress site

Analyst Recognizes $1,000 Silver At Share Maximum - Enterprise Expert

"[T]he big hubristic 'tell' will be gold," Hartnett wrote in a note to clients on Friday. "A sudden gap lower in the gold price to below $1,000/oz should coincide with the final thrust higher in stocks, both indicating capitulation of the 'stubborn bears,' the end of the 'melt-up' and the next opportunity to get tactically bearish. We increasingly fear next year's high in stocks come early." In his note, Hartnett wrote that stocks have not rallied to highs because of strong growth from US companies or the US labor market, but because of central bank deflation "panic." Late last month, the Bank of Japan announced additional stimulus. And just last week, European Central Bank president Mario Draghi said the ECB would look to increase the size of its balance sheet and that ECB members were unanimous in pushing for more stimulus if needed. "Confidence is broadening that US growth & QE can and will solve all," Hartnett wrote, "and that any 2015 normalization of QE will be devoid of negative consequences. http://www.businessinsider.com/analyst-sees-1000-gold-at-stock-peak-2014-11#ixzz3Igwad5PY

The Stock Market Is Overvalued By 100% - Business Insider

Right now stocks as a multiple of last years expected earnings may look only modestly over valued or modestly richly valued. Really http://online.wsj.com/articles/hungary-to-use-official-exchange-rates-to-convert-forex-mortgages-1415568621 if you look at the measures of valuation more? info… that are most correlated to the returns that stocks deliver over time say over seven years or over the next 10 years the S&P 500 in our estimation is about double the level of valuation that would give investors a normal rate of return. So right now, we've got stocks valued at a point where we estimate the 10 year prospective return on the S&P 500 will be about 1.6 to 1.7% annualized talking right now with the S&P 500 at 2032 as of todays close. Chris Martenson:I guess 1.6 or 7% doesnt sound bad if you are getting 0% on your risk-free money, I guess. But this says that any move by the Fed to normalize which means rates have to go up any move to drain liquidity from the system is going to have its own impact. If we held all things equal, a normalization effort is going to then basically expose that the stock market is roughly overvalued by 100%. John Hussman: 100%, yes. http://www.businessinsider.com/the-stock-market-is-overvalued-by-100-2014-11

Research : Rings Opening Bell at The Nasdaq Stock Market in Celebration of Its IPO | 4-Traders

" INC Research has become an increasingly significant force in the clinical http://www.wausaudailyherald.com/story/life/2014/11/11/ywca-investing-future/18654891/ development industry over the past three years, demonstrating tremendous growth in our capacity and capability to deliver the therapeutic expertise and global clinical development services our biopharmaceutical customers require. Our success could not have been achieved without the passion and contributions of our more than 5,000 employees worldwide who are committed to making life-enhancing drugs a reality for patients around the world. We thank them for their efforts and look forward to this next chapter in our growth that will create even greater opportunities for our stakeholders." As a leading global CRO based on revenues, INC Research is exclusively focused on Phase I to IV clinical development services for the biopharmaceutical and medical device industries. Industry sources estimate the market for Phase II toIV clinical development services is expected to grow at a rate of 8 to 9 percent annually through 2018, driven by a combination of increased development spend and further outsourcing penetration. INC Research's deep therapeutic expertise, global reach and capabilities, and ability to conduct increasingly complex clinical trials and maintain strong site relationships provide the Company with a competitive edge to take advantage of the growing outsourcing trend. To view the video of the ceremony or for a photo of the Company's leadership team at the moment the bell rang, please visit the Investor Relations section of the Company's website at investor.incresearch.com. About INC Research INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey . is headquartered in Raleigh, NC , with operations across six continents and experience spanning more than 100 countries. http://www.4-traders.com/RESEARCH-HOLDINGS-INC-18460923/news/Research--Rings-Opening-Bell-at-The-Nasdaq-Stock-Market-in-Celebration-of-Its-IPO-19367859/